REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

 

Current tag:

UK Chemical Industries’ Lessons From the Recession

Dr John Saul, past President of the British Chemical Industries Association on Issues For a Sustainable Future of the Sector

Dr John SaulApril 2011. The chemicals industry in the UK his coming out of some quite difficult times. How sustainable is recovery? In the exclusive interview with B2Bioworld Dr John Saul, past President of CIA provides an outlook on the future of the UK chemicals industry leveraging British Pound, US Dollar and Euro, while seeking opportunities within the UK, in the EU, and emerging countries. Demanding tasks lie ahead. While pharma is the draught horse of the UK chemicals industry, how competitive is the rest of it on a global scale? What is the strategy to reduce dependency on fossil energies and in which ways does it account for nuclear or renewable ones? How is REACH regulations viewed from within the country? Last not least, what are prospects that policy makers coherently attend to industry interests given a rather fragmented scene of lobbying organisations and preferences for the finance and banking sector?

Related Articles

Clariant & Süd-Chemie: “rather limited synergies”

Dr. Günter von Au, Designated Board Member Clariant AG and CEO Süd-Chemie AG

Fighting Crisis in the Chemicals Industry!

Giorgio Squinzi, CEO of Mapei SpA and past President of Italy’s Federchimica

Turkish Chemicals Industry: Opportunities and Threats

Timur Erk, President of TKSD on re-building Turkey’s chemicals industry

What Future for the Chemicals Industry?

Dr. Stefan Marcinowski, Member of the Board of Executive Directors of BASF SE



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

interview 8 pages

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Prof. Andreas BuschJanuary 2011. An unmasked account of decisions about investing into cancer stem cell research and the fate of regenerative medicine projects in Japan. Dr Busch summarises results and evaluates technology platforms like novel antibodies and wnt mechanisms. He voices his expectations from current key drug development partnerships, in particular with Oncomed and Micromet. Will these include companion diagnostics? To what extent does Bayer retain respective intellectual property rights? A comment on personalised medicine and cancer stem cells research pursued by Merck KGaA and others. What are prospects for classic oncology drugs?

 

 

 

Related Articles

Horizon Discovery: Mitigating risks and developing the U.S. business

Tasks ahead for Eric Rhodes, the new CTO

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

Prof Walter Kolch on the approach taken by Systems Biology Ireland


B2Bioworld Stem Cell Insights Collection 2010:

Issues and Evaluation from Pharma Leaders

 

Dr Patrick Vallance, GSK:

Stem Cell Research Now and in the Future

 

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director

 



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

3 pages, exclusive

Elmar Schnee resigns from Merck KGaA's Board ... and Chemgenex?

Wolf G Kroner

 

Darmstadt, 13-12-2010. Merck Serono’s Chief Executive Officer and General Partner of Merck KGaA is resigning from his duties for ”personal reasons” end of year, his company told in a press release today. The leave of Mr. Schnee comes as surprise given his continued merits in profitably streamlining Merck’s pharma divisions and changing Serono’s culture of youthful impetuosity to a more sustainable one embodied by the Merck family. He is followed by Stefan J. Oschmann who has been lately President of Emerging Markets of Merck & Co, and will move from MSD’s headquarters at Whitehouse Station, New Jersey (US) to Darmstadt beginning January 2011.

(C) Wolf G Kroner 2010Mr. Schnee (51) is a marketing veteran in the pharmaceutical industry where we worked with Fisons Pharmaceutical, Sanofi-Synthélabo, and UCB Pharma before joining Merck in 2003. He started as Managing Director of Merck Santé SAS at Lyon (FR) with responsibilities to commercialise Merck’s prescription medicines and managing distribution alliances. Since 2006 he is General Partner of Merck KGaA. In the group he is responsible for the pharmaceutical business including consumer healthcare. Currently, one of Mr. Schnee’s very few external duties is with ChemGenex Pharmaceuticals (ASX: CXS; American Depository receipts: CXSPY). Since 2007 he is Director of Board of this company and the architect of acquiring shares for Merck. With 8.49% Merck Santé is CXS’ third largest shareholder. This has raised questions, how the resignation will affect ChemGenex.

Chemgenex is rapidly approaching the market stage and aims for a global reach. Its most advanced drug candidate is omacetaxine mepesuccinate (trade name: OMAPRO) for patients with chronic myeloid leukemia (CML). It is directed to Philadelphia chromosome positive chronic myeloid leukaemia in patients who have the T315I Bcr-Abl kinase domain mutation and who are resistant to prior therapy of Novartis’ imatinib (trade name: Glivec). In fall 2008 the company already established European operations at Lyon to pursue EU marketing authorisation of OMAPRO and has received an orphan drug designation meanwhile. With expectations of approval by EMEA ChemGenex has entered with Hospira into a marketing agreement for Europe, the Middle East and parts of Africa in December 2009. In the United States ChemGenex intends to commercialise itself the drug. However, in March it experienced a setback in the US as an FDA advisory committee recommended submission of ”a well characterized” diagnostic test instead of the ones used in previous trials in order to identify patients with the mutation prior to approval of the drug. In this situation CXS is to benefit more than ever from Elmar Schnee’s advice as he “will continue to support Chemgenex on the board of directors”, at least during the next 12 months Dr Greg Collier, the company’s CEO told B2Bioworld.
 
Given the abrupt departure in conjunction with the rapid nomination of Dr. Oschmann to Mr. Schnee’s post, observers say, that the present resignation might be more related to internal dynamics of Merck than to external companies, a view which Mr. Schnee is confirming. Asked about his plans, in particular with regard to Chemgenex Pharmaceuticals, he told B2Bioworld: ”I will have to take it apart, if I have a moment to spare. Up to now I have been fully occupied, and then, we’ll see.”

 

This article is offered to you for free reading by B2Bioworld - Quality News.

 

(C) B2Bioworld 2010. All Rights Reserved

Stem Cell Insights Collection 2010

Issues and Evaluation from Pharma Leaders

How does the pharma industry view application of stem cell technologies? Where are R&D efforts needed, and where does academic research not fulfill expectations? What is the role of suppliers in the field?

Read fresh answers from the leaders, provided exclusively to readers of B2Bioworld. Published only here, and all in one.

 

(C) Boehringer Ingelheim(C) Wolf G Kroner 2009(C) Wolf G Kroner 2009(C) Hoffmann-La Roche 2009

 

We are obliged to more and more move away from animal models
- Prof. Andreas Barner, Boehringer Ingelheim


Preparing for Another Level of Innovation
- Dr Mark Fishman, Novartis


Clear away complete confusion of terms
- Dr Bernhard Kirschbaum, Merck Serono


Stem Cells: a discovery tool and a potential therapeutic modality
- Dr Jonathan Knowles, Hoffmann-La Roche

 

(C) R.McKernan 2009(C) Wolf G Kroner 2009(C) M. Krogsgaard(C) K. Stoeckli

 

It really started last year…
- Dr Ruth McKernan, Pfizer Regenerative Medicine


Stem Cells and Vaccines Production
- Dr Majid Mehtali, Vivalis


Doing our business a little bit differently than the others in the industry
- Dr Mads Krogsgaard, Novo Nordisk


Triggering Regenerative Functions with Transplanted Cells and Small Molecules
- Dr Kurt Stoeckli, Biological Sciences/Discovery Sanofi-Aventis

 

(C) P. Vallance(C) Hugh Ilyine 2009(C) S. Tegethoff 2009(C) D. Hay 2009


Stem Cell Research in GlaxoSmithKline and Beyond
- Dr Patrick Vallance, GlaxoSmithKline Drug Discovery


Stem Cells – Failings and Deliveries
- Hugh Ilyine, Consultant & Guest Editor


Patenting Stem Cells
- Dr. Sebastian Tegethoff, 24IP


Drug Testing with Embryonic Stem Cells – Towards Standards For Assays
– Dr David C Hay, University of Edinburgh, MRC Centre for Regenerative Medicine


L’Oréal avance dans les cellules souches
- Report by Hélène Guyot (with summary in English)


Buy the Entire Collection of Articles on Stem Cells here

 

Related Article 

Bayer AG: New Stakes in Stem Cells
- Prof. Andreas Busch, Bayer AG



If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

13 articles, advert-free

Top 10 Tags

All Tags (2094)